BioCentury
ARTICLE | Top Story

Merck forms follow-on biologics unit

December 10, 2008 1:21 AM UTC

Merck (NYSE:MRK) said it formed Merck BioVentures to develop follow-on biologics (FOBs). The first candidate in development is MK-2578, a pegylated erythropoietin (EPO) in Phase I testing for anemia, ...